Eton Pharmaceuticals, Inc has entered into an asset purchase agreement to acquire Increlex® (mecasermin injection) from Ipsen S.A. The acquisition aligns with Eton's mission to develop and distribute medicines that have a life-changing impact for patients with ultra-rare conditions.